Section 01
What Selank Actually Is
⚠️What the Evidence Does and Doesn't Support
The primary human trial, a 2008 Russian RCT involving 62 patients, ran for 14 days. It showed anxiolytic effects comparable to low-dose phenazepam (a Russian benzodiazepine) without sedation, amnesia, or tolerance. That is meaningful. It is also one small trial, conducted by the same institution that developed the compound, with no independent Western replication. There is no Phase III trial. There is no FDA-recognized efficacy data. Non-responder rates in the human trial were not published separately. Approximately 20 to 30% of patients in Russian anxiolytic studies of this type show minimal response to treatment. This compound is unlikely to be different.
Selank is a synthetic heptapeptide developed in Russia in the 1980s and 1990s by the Institute of Molecular Genetics of the Russian Academy of Sciences. Its structure is a stabilized analog of tuftsin, an endogenous tetrapeptide produced by the spleen with roles in immune regulation. The research team extended tuftsin's structure (TKPR) with a four-amino-acid tail (PGP) to create TKPRPGP, a compound stable enough to survive nasal administration and small enough to cross the blood-brain barrier. Russia registered Selank as a prescription medication for generalized anxiety disorder and neurasthenia. The United States has never reviewed it for approval.
What Selank is not: a fast, powerful sedative. It does not produce the acute calm of a benzodiazepine or the euphoria of phenibut. Clinical users describe its effect as a reduction in anxious reactivity, a quieting of alarm signals rather than a pharmacological dampening of consciousness. If you are looking for a compound that will stop a panic attack in twenty minutes, Selank is not the right tool. If you are looking for something that reduces baseline anxiety across a 14-day course without producing dependence or tolerance, the existing evidence supports that case, within significant limits described in the sections below.
1980s
Decade of original development: Institute of Molecular Genetics, Russia
2–3 hrs
Intranasal half-life; multiple daily doses required for sustained effect
62
Total patients in the primary human RCT, the only controlled trial with published English-accessible data
Section 02
Who It's Actually For
Five distinct consumer profiles use Selank. Four are reasonable candidates for physician-supervised protocols. One, the acutely anxious person seeking immediate panic relief, is not.
| Profile | Primary Motivation | Fit | Key Consideration |
|---|---|---|---|
| Benzodiazepine Refugee | Has used prescribed benzos, experiences tolerance or dependence, seeks non-addictive alternative | High Fit | Requires physician evaluation and documented benzo history. Not a DIY protocol. |
| Burnout Professional | High-stress work, subclinical anxiety, cognitive edge sought without sedation or SSRI blunting | Good Fit | Multiple daily dosing required. Morning dose alone will not provide all-day coverage. |
| SSRI-Disappointed | Tried SSRIs, found emotional blunting or libido effects unacceptable | Good Fit | Selank's non-blunting profile is its most consistent differentiator. Outcomes vary. |
| Anxiety-Primary Patient | Diagnosed GAD or similar, seeking alternatives or adjuncts | Moderate Fit | Does not replace psychiatric care. Use alongside, not instead of, existing treatment. |
Performance Athlete Seeking fat loss, muscle gain, hormonal optimization | Poor Fit | No documented anabolic effects | Selank is an anxiolytic. It is not a body composition compound. |
Profile
Primary Motivation
Fit
Key Consideration
Profile
Primary Motivation
Fit
Key Consideration
Profile
Primary Motivation
Fit
Key Consideration
Profile
Primary Motivation
Fit
Key Consideration
Profile
Seeking fat loss, muscle gain, hormonal optimization
Primary Motivation
Fit
Key Consideration
🔬The Undersold Immune Angle
Selank was developed as a tuftsin analog. Tuftsin is an endogenous immune regulator. Multiple animal studies show Selank normalizes IL-6 and modulates immune signaling: not immunosuppression, but what researchers describe as immune system normalization. For patients whose anxiety is inflammatory in origin or who experience stress-driven immune dysregulation, this secondary mechanism may be clinically relevant. Human data on this endpoint is limited to preliminary findings. It is not a confirmed therapeutic effect in the Western evidence hierarchy, but it is a real mechanism worth monitoring in individual responses.
Section 03
How It Works
Selank's mechanism separates it from every conventional anxiolytic on the market. Understanding the distinction is essential, because it explains both the benefit and the evidence gap.
The GABA Question
Benzodiazepines bind directly to GABA-A receptors as positive allosteric modulators. They increase chloride ion flow into neurons, producing fast, powerful calming effects. The cost is well-documented: GABA-A receptors downregulate in response to chronic stimulation, producing tolerance. Remove the drug and the receptor is now undersensitized, producing rebound anxiety and withdrawal. This mechanism is why benzodiazepines are among the most difficult drug classes to discontinue.
Selank's Upstream Approach
Selank does not bind to GABA-A receptors directly. A 2016 study published in PMC (PMC4757669) demonstrated that Selank administration modulates the expression of genes involved in GABAergic neurotransmission, working at the level of gene expression rather than receptor binding. This upstream approach is the scientific basis for the "no tolerance" finding in the 14-day RCT. If the receptor is not being directly stimulated, there is no direct downregulatory signal. What happens over months of use, or in patients with atypical GABA system genetics, has not been formally studied.
Additional Mechanisms
Beyond GABA system modulation, Selank inhibits the enzymatic degradation of enkephalins (endogenous opioid-like peptides that regulate pain, stress, and mood). It has also been shown to stimulate BDNF (brain-derived neurotrophic factor) expression, a finding with implications for neuroplasticity and long-term stress resilience. And as a tuftsin analog, it interacts with immune signaling via IL-6 normalization. These are complementary mechanisms, not primary ones. The anxiety effect is the clinical anchor.
🔬The Gene-Level Distinction from Benzodiazepines
The 2016 PMC-indexed study showed that Selank changes the expression of GABA-related genes rather than competing for receptor binding sites. This is a fundamentally different pharmacological interaction than classical GABAergic drugs. In the 14-day clinical trial, no tolerance development was observed. This is consistent with the gene-expression mechanism: the receptor is not being directly stimulated, so it has no direct signal to downregulate. The critical unknown: whether this tolerance-free profile holds in longer treatment courses, across diverse genetic backgrounds, or at doses higher than those studied.
"Finally, something that modulates GABA without hijacking the receptor."
— Community framing, multiple forum threads
"The peptides are probably more interesting than skeptics assume, and less proven than enthusiasts claim."
— PeptideDeck community analysis
Section 04
Realistic Expectations
Most sources that discuss Selank describe what it can do. This section describes what you will actually experience, including the meaningful minority of users for whom it does little.
First Administration
Most users notice acute anxiolytic effect within 30 to 60 minutes of intranasal administration. The sensation is reduction in anxious reactivity — less alarm, quieter nervous system. Not sedation. Not euphoria. Some users notice nothing on day one at a dose that will work consistently at day seven. First-dose non-response is not a reliable signal.
Dose Calibration Week
Intranasal dose standardization is critical in the first week. The spray delivery problem (described in Section 05) means many users are dosing imprecisely without knowing it. This week should be used to establish consistent delivery technique, dosing frequency (two to three times daily), and timing relative to food and sleep.
Therapeutic Course
The Russian clinical protocol runs 14 days. This is the evidence-supported therapeutic window. Consistent users typically report stable anxiolytic effect by end of week two. Sleep quality improvement and reduced stress reactivity are the most commonly reported secondary effects. Some users report mild fatigue in the first 3 to 5 days that typically resolves.
End of First Course
Standard protocol completes here. Results should be assessed. Non-responders — estimated at 20 to 30% based on general anxiolytic trial data, with no Selank-specific number published — should discontinue rather than extend. Extending a non-effective course does not typically convert to efficacy.
Off-Cycle
Effects diminish within days of stopping. No documented withdrawal syndrome in any published study. No rebound anxiety documented. This is clinically meaningful: the absence of withdrawal is one of Selank's most credible differentiators from benzodiazepines. Long-term effects beyond repeated 14-day courses have not been formally studied.
"The first dose gave an almost euphoric sense of calm and clarity. This is what I've been looking for for fifteen years."
— Selank user, vendor review site
"Helped beyond words. I'd been on various psychiatric medications with little success. Selank was different."
— Selank patient, clinical review
⚠️Non-Responder Rate
No Selank-specific non-responder rate has been published in English-accessible literature. The 62-patient RCT reported group-level outcomes, not individual response distribution. Based on typical anxiolytic trial populations, an estimated 20 to 30% of users will experience minimal effect. This is not a product quality problem. It is a pharmacogenomic reality. Individual variation in GABA system genetics, enkephalin receptor density, and tuftsin receptor expression are likely predictors of response that have not been studied in this compound.
⚠️What Happens When You Stop
Selank's anxiolytic effects diminish within days of discontinuation. No published study documents a withdrawal syndrome. No rebound anxiety has been documented in clinical trial data. This is a meaningful difference from benzodiazepines and phenibut, both of which carry documented and sometimes severe discontinuation effects. However: the absence of documented withdrawal is not the same as a guarantee of withdrawal-free experience across all users. Anyone transitioning off longer-term Selank use should do so with physician guidance.
Section 05
Dosing Protocol
The most persistent, most practically harmful problem in Selank's consumer history is the absence of standardized intranasal dosing. Every guide states a dose in micrograms. No guide tells you how many micrograms are in your specific spray device. Gray-market products range from 100 to 300 mcg per pump actuation across different vendors and device types. The Russian pharmaceutical standard — 0.15% concentration, approximately 75 mcg per 0.5 mL actuation — has never been universally adopted by US sources.
Russian clinical practice uses Selank 0.15% intranasal solution. Two drops into each nostril, three times daily, for up to 14 days. Each drop delivers approximately 37.5 mcg, making each bilateral administration approximately 150 mcg and total daily dose approximately 450 mcg. This is the evidence-supported dose range. Many US gray-market users inadvertently dose below this threshold because their spray delivers less than expected from an improperly primed or low-concentration device.
| Protocol | Dose | Frequency | Evidence |
|---|---|---|---|
| Russian Clinical Standard | 150 mcg per administration (2 drops/nostril, 0.15%) | 3x daily, up to 14 days | Supported — 2008 RCT |
| VitalRx Protocol | 250–500 mcg intranasal per administration (physician-determined) | 2–3x daily, 14-day courses | Physician-Supervised 503B standardized concentration. |
| Community Minimum (Gray Market) | 250–300 mcg | 1–2x daily | Limited — No Standardized Delivery |
| Community Maximum (Gray Market) | 600–900 mcg | 2–3x daily | Exceeds Clinical Study Doses |
| N-Acetyl Selank Amidate | Lower mcg (30–50% higher bioavailability) | 1–2x daily | Insufficient Human Data |
Protocol
Dose
Frequency
Evidence
Protocol
Dose
Frequency
Evidence
Protocol
Dose
Frequency
Evidence
Protocol
Dose
Frequency
Evidence
Protocol
Dose
Frequency
Evidence
Administration technique: Tilt head slightly forward, not back. Direct the spray toward the lateral nasal wall, not straight up toward the sinuses, not down toward the floor. Breathe gently through the nose during administration. Do not sniff forcefully, which can draw solution into the pharynx. Proper technique vs. poor technique can account for 30 to 40% variation in mucosal contact and absorption.
"I was worried about the doses varying. I couldn't find consistent information on how to reconstitute my vial for my specific bottle type."
— Reddit user, r/Nootropics
✦How VitalRx Eliminates the Spray Bottle Lottery
VitalRx's 503B-sourced Selank ships as a pharmaceutical-grade nasal spray formulated to a verified concentration, in a standardized actuator device with a known per-pump delivery volume. You know exactly how many micrograms are in each administration. This is not a gray-market product reconstituted from bulk powder into a nasal bottle of unknown actuation volume. It is a clinically formulated product manufactured under CGMP standards. This eliminates the most common cause of Selank "failure" in self-sourcing populations: dosing imprecision.
📌The N-Acetyl Selank Amidate Distinction
N-Acetyl Selank Amidate is a modified form with an acetylated N-terminus and amidated C-terminus. It has a reported half-life of 4 to 6 hours versus standard Selank's 2 to 3 hours and is estimated to be 30 to 50% more bioavailable. It is NOT the same compound. Do not apply standard Selank dosing to the amidate form. Patients who received the amidate form from a gray-market vendor and apply standard Selank dosing may be taking a significantly higher effective dose than intended. Your VitalRx physician will specify which formulation you are receiving.
Section 06
Cycling: Evidence vs. Myth
Almost every Selank guide recommends cycling, typically 4 to 6 weeks on, 2 to 4 weeks off. Almost none of them cite a source for this recommendation. This section separates what the evidence says from what the community has inherited from other GABA-active compounds.
🔬What the Clinical Data Actually Shows
The Russian clinical protocol for Selank is a 14-day therapeutic course, not a cycling protocol in the biohacking sense. After 14 days, patients are typically reassessed, and additional courses may be prescribed if clinically indicated. The 14-day trial found zero evidence of tolerance development within that window. The 2016 gene-expression study provides a mechanistic rationale for why tolerance may be less likely than with direct GABA-A receptor modulators. Neither of these findings confirms what happens at 6 weeks, 12 weeks, or 6 months of continuous use.
| Claim | Source | Evidence Status |
|---|---|---|
| "Cycling is required to prevent tolerance" | Community consensus, most vendor guides | No Evidence Tolerance not documented; claim borrowed from benzodiazepine protocols. |
| "GABA receptor desensitization risk with continuous use" | Community inference | Theoretical Plausible but not documented for Selank. Mechanism makes it less likely than direct GABA-A modulators. |
| "14-day courses with breaks reflect the clinical standard" | Russian prescribing practice | Supported This is how Selank is prescribed in Russia. Reasonable clinical anchor. |
| "Long-term continuous use is safe" | Gray-market community | No Evidence Simply not studied. Absence of evidence is not evidence of safety. |
| "6 weeks on, 4 weeks off produces best outcomes" | Common gray-market advice | No Evidence This specific schedule has no clinical basis in Selank literature. |
Claim
Source
Evidence Status
Claim
Source
Evidence Status
Claim
Source
Evidence Status
Claim
Source
Evidence Status
Claim
Source
Evidence Status
VitalRx's approach: 14-day courses aligned with the Russian clinical standard, with physician evaluation between courses to assess continued appropriateness. This is not a permanent subscription. It is a physician-guided therapeutic protocol. Course frequency and duration are determined by clinical response, not by a vendor's recurring billing cycle.
Section 07
Ready to Use
The gray-market Selank experience involves buying bulk powder, sourcing bacteriostatic water, locating an appropriate nasal spray device with a known actuation volume, calculating the correct dilution for your target concentration, reconstituting the peptide correctly, and hoping the device you ordered delivers what the spec sheet claimed. Most users get at least one of these steps wrong in a way they never discover. VitalRx eliminates all of it.
✦Pre-Formulated. Verified Concentration. Pharmaceutical-Grade.
Your VitalRx Selank arrives as a ready-to-use nasal spray formulated to a verified concentration in a CGMP-certified facility. The actuation volume is standardized. The concentration is tested. The cold chain is maintained from manufacturing through delivery. No reconstitution. No powder. No improvised spray bottles. The spray you receive delivers what the label states, every time.
0
Reconstitution steps — pre-formulated, nothing to mix
503B
Registered outsourcing facility — pharmaceutical CGMP standards
Cold
Chain maintained — verified concentration, proper handling from manufacture to your door
Your protocol package includes the Selank nasal spray, a patient information sheet with your physician-determined dosing instructions, and a labeled delivery schedule. All labeling is physician-issued, pharmacy-stamped, and compliant with your state's prescription dispensing requirements.
Storage: Store the nasal spray under refrigeration (2–8°C / 36–46°F). Do not freeze. Keep out of direct light. The product is formulated for stability in cold-chain storage and has a manufacturer-verified shelf life. If the product arrives warm, contact VitalRx before use.
Section 08
Getting the Most From Your Protocol
Selank's effects are real. They are also dose-dependent, timing-dependent, and affected by factors most users do not control or even consider. This section covers what determines whether your protocol works and why the community's most common failure mode is not pharmacological, it is behavioral.
🔬Why Multiple Daily Doses Matter
Intranasal Selank has a half-life of 2 to 3 hours. Its anxiolytic effects fade within 4 to 6 hours. This means a morning-only dose does not provide afternoon anxiety coverage. The Russian clinical protocol specifies three administrations daily for a reason: that frequency maintains meaningful plasma levels across waking hours. Users who dose once daily and report "Selank didn't work" may simply have dosed once. One daily administration is not the clinical protocol.
🔬Food Timing and Nasal Absorption
No food-interaction data exists for intranasal Selank specifically. However, nasal mucosa congestion from eating-related vasodilation can affect absorption. Best practice: administer at least 30 minutes before or 60 minutes after a meal, when nasal mucosa is in its baseline state. Avoid administration immediately following decongestant use, which changes mucosal characteristics. This is best practice for intranasal peptide administration generally.
🔬Sleep and Anxiety Modulation
Sleep deprivation is among the most reliable triggers of anxiety sensitization. Selank's BDNF-stimulating and stress-regulatory effects operate best in a nervous system that is getting adequate recovery. Users who are chronically sleep-deprived and using Selank for anxiety management may find the compound's effects are partially canceled by ongoing sleep-deficit driven neurological stress. Sleep hygiene is not a soft recommendation: it is a protocol variable.
🔬The Full Course Matters
The clinical evidence base for Selank is built on 14-day courses. Assessing efficacy at day 4 or day 7 is premature. The gene-expression mechanism takes time to establish a stable anxiolytic baseline. The community's most common compliance failure is abandoning the course too early after an unimpressive first week. If day 10 and day 14 are substantially different from day 3, that is the compound working as the mechanism predicts.
🔬What Labs Can Show (If You Want the Data)
Labs are not clinically required for Selank at standard therapeutic doses. There is no metabolic monitoring need comparable to growth hormone peptides. However, some patients want objective data. A baseline and post-course BDNF level can quantify the neurological response. Inflammatory markers (hsCRP, IL-6) can document immune modulation effects in patients using Selank for stress-related inflammation. These are optional, not billed as part of the standard VitalRx Selank protocol. Ask your physician if you want to add them.
Section 09
Stacking
Selank stacks most logically with compounds that complement its anxiolytic and neuroprotective effects, not with compounds that duplicate its GABA system activity. The most important stacking rule is also the most consistently violated one: never combine multiple GABAergic compounds without physician oversight.
| Compound | Class | Mechanism Rationale | VitalRx Availability |
|---|---|---|---|
| Semax | Neuroprotective peptide | Cognitive activation complement. Semax is dopaminergic/BDNF-stimulating; Selank is anxiolytic. Together they address both underactivation (low focus) and overactivation (anxiety) in burnout. | Available |
| BPC-157 | Systemic tissue peptide | Supports gut-brain axis integrity, reduces neuroinflammation. No GABA overlap. | Available |
| Thymosin Beta-4 | Immune/tissue regulatory | Complements Selank's immune normalization through distinct pathway (actin sequestration, anti-inflammatory). No CNS interaction risk. | Available |
| Magnesium Glycinate | Supplement — GABAergic support | Supports GABA receptor function through cofactor activity. Community identifies mag + Selank as 'more predictable and reliable' than either alone. | OTC, Patient-Sourced |
Compound
Class
Mechanism Rationale
VitalRx Availability
Compound
Class
Mechanism Rationale
VitalRx Availability
Compound
Class
Mechanism Rationale
VitalRx Availability
Compound
Class
Mechanism Rationale
VitalRx Availability
"Magnesium, glycine, and Selank are way more predictable and reliable [than other anxiolytic stacks] based on my reactions."
— Longecity forum user
⚠️What Not to Stack — and Why
Benzodiazepines: Combining with Selank creates additive CNS depression through overlapping but distinct mechanisms. Do not combine without direct physician instruction.
Phenibut: Strong GABA-B agonist with documented dependence and withdrawal risk. Adding Selank's GABAergic modulation to phenibut creates an unpredictable combined CNS load. Phenibut's dependence liability does not disappear because Selank is in the stack.
Alcohol: Alcohol is a GABA-A positive modulator. Combining with Selank during a therapeutic course adds unpredictable CNS depression and may compromise sleep architecture needed for optimal response. Avoid alcohol within the Selank dosing window.
Section 10
What This Actually Costs
⚠️The Number Most Sources Hide
Gray-market Selank powder costs $30 to $60 per vial. That vial needs to be reconstituted, transferred to a spray bottle, and dosed from a device with unknown actuation volume. Then the user discovers: the concentration math requires pharmaceutical knowledge, the spray bottle actuates differently than expected, and they have no idea whether they are dosing 100 mcg or 400 mcg per pump. The product is "cheap." The actual cost of getting a clinical outcome is not, because most users underdose for weeks before either giving up or overshoot unknowingly.
| Option | Cost | What's Included | Quality |
|---|---|---|---|
| Gray Market (Powder + DIY) | $30–$60/vial + spray bottle + bac water | Product only. No physician. No verified concentration. | Unregulated |
| Other Medical Clinics | From $150 advertised. Labs, consult fees not publicly disclosed. | Varies by clinic. Verify all-in pricing. | Verify Before Committing |
| VitalRx, 14-Day Course | Pricing confirmed at consult | All-In Physician consult, 503B nasal spray, standardized dosing, cold-chain shipping. | 503B Registered |
Option
Cost
What's Included
Quality
Option
Cost
What's Included
Quality
Option
Cost
What's Included
Quality
Gray Market
$30–$60/vial
Powder only. DIY reconstitution. No physician, no verified concentration.
UnregulatedOther Clinics
From $150
Labs, consult fees not publicly disclosed.
VerifyVitalRx, 14-Day Course
Confirmed at consult
503B nasal spray, physician consult, standardized dosing, cold-chain shipping.
All-InPrice Breakdown
Medication
503B Selank Nasal Spray
Verified concentration, standardized actuator
Pre-formulated, physician-labeled, cold-chain shipped. No reconstitution.
Physician Oversight
Licensed Physician Consultation
Included
Intake assessment, dose determination, 14-day course review. Not billed separately.
Labs
Not Clinically Required
Optional
BDNF and inflammatory markers available on request. Standard protocol does not require monitoring.
Delivery
Cold-Chain Shipping
All 50 states
Temperature-controlled packaging, insured delivery. Included in pricing.
✦Why This Is a Course, Not a Subscription
VitalRx Selank protocols are structured as 14-day therapeutic courses, not monthly subscriptions. You are not auto-billed for a recurring supply. Each course is physician-reviewed before dispensing. If a subsequent course is clinically appropriate, your physician prescribes it. If it is not, it stops. The business model follows the clinical evidence, not the other way around.
Section 11
Legal Access in All 50 States
Selank's regulatory history in the United States is more favorable than the community currently believes, and most of the community does not know why.
Removed from FDA Category 2
Selank withdrawn from prohibited list September 27, 2024
503B Registered Facility
Pharmaceutical CGMP standards — not affected by 503A restrictions
Physician Prescription Required
Off-label prescribing through legitimate compounding pathway
All 50 States
Available through VitalRx's licensed physician network nationwide
Layer 1: What the FDA Category 2 Placement Was
In 2023, Selank acetate (TP-7) was nominated for placement on the FDA's Category 2 interim bulks list for 503A compounding pharmacies. Category 2 placement would have prohibited standard compounding pharmacies from manufacturing the compound. The FDA's accompanying language raised concerns about immunogenicity risk from impurities in substandard compounding processes. This created significant community concern and depressed access to Selank through legitimate channels.
Layer 2: What Actually Happened
On September 27, 2024, the nominators withdrew their nomination of Selank acetate from Category 2 consideration. Selank was removed from the prohibited list. It is not currently on the FDA's Category 2 list. Most community discussions from late 2024 and early 2025 still reference the ban as active. This is outdated information. The immunogenicity concern raised by the FDA applied specifically to substandard compounding processes, not to the compound itself. Pharmaceutical-grade Selank manufactured under CGMP conditions does not carry the same risk profile.
Layer 3: The 503B Access Pathway
VitalRx sources from a 503B FDA-registered outsourcing facility. 503B facilities operate under pharmaceutical CGMP standards, the same manufacturing quality requirements applied to FDA-approved drugs. This is a distinct pathway from the 503A compounding pharmacies that were the subject of the nomination process. A physician prescription through VitalRx's licensed physician network constitutes legal, compliant access to Selank in all 50 states.
✦Off-Label Prescribing Is Standard Medical Practice
Selank is not FDA-approved for any indication. Your VitalRx physician is prescribing it off-label, a legally and clinically standard practice used for thousands of medications in the United States every day. Off-label prescribing requires a physician-patient relationship, informed consent, clinical judgment, and a legitimate therapeutic rationale. VitalRx's physician network provides all of these. The prescription is real. The pharmacy is real. The clinical oversight is real.
📌Important Legal Caveat
Regulatory status can change. The information above reflects VitalRx's understanding as of March 2026, based on FDA interim bulks list updates and applicable compounding pharmacy law. VitalRx's legal compliance posture is reviewed by compounding pharmacy counsel. If you have questions about specific legal access in your state, your VitalRx physician can provide additional guidance.
Section 12
Community Q&A
The following questions come directly from peptide community forums, Reddit threads, and patient intake forms. Answers are honest, including when the honest answer is "we don't know."
Section 13
The VitalRx Model
This guide disclosed a non-responder rate. It told you what happens when you stop. It described the limitations of a 14-day Russian RCT. It named the compounds you should not combine with Selank. That is the VitalRx editorial standard, applied consistently across every protocol guide we publish. If that is the kind of transparency you want from your peptide provider, here is how we operate.
503B Pharmaceutical Sourcing
Selank manufactured in a 503B FDA-registered outsourcing facility under pharmaceutical CGMP standards. Verified concentration. Standardized delivery device. Cold-chain shipping. Not a bulk powder reconstituted into a spray bottle of unknown actuation.
Licensed Physician Oversight
Your VitalRx protocol is prescribed by a licensed physician. Not a nurse practitioner. Not a form-and-click intake. A physician who reviews your intake, assesses appropriateness, determines your dose, and is available for follow-up questions. Off-label prescribing requires physician judgment. We provide it.
Honest Education First
Every VitalRx protocol guide leads with limitations. We tell you the non-responder rate. We tell you what happens when you stop. We tell you what the evidence says and what it doesn't. This is not a disclaimer. It is the service. An educated patient has better outcomes.
Legal Access in All 50 States
VitalRx's 503B pharmacy pathway provides legally compliant access to Selank in all 50 states. No gray-market sourcing. No import risk. No ambiguity about what you're taking. Physician-labeled, pharmacy-dispensed, cold-chain delivered.